Brief: Evofem Biosciences Announces Successful Type C Meeting With FDA For STI Prevention Product Candidate
30/11/2021 13:08
Nov 30 (Reuters) - Evofem Biosciences Inc EVFM.O :
* EVOFEM BIOSCIENCES ANNOUNCES SUCCESSFUL TYPE C MEETING
WITH FDA
FOR STI PREVENTION PRODUCT CANDIDATE
* EVOFEM BIOSCIENCES INC - COMPANY EXPECTS TO REPORT
TOP-LINE
EVOGUARD DATA IN SECOND HALF OF 2022
* EVOFEM BIOSCIENCES INC - ANTICIPATED PDUFA DATE IN SECOND
HALF
OF 2023 DUE TO EXPEDITED REVIEW AFFORDED BY FAST TRACK
DESIGNATIONS FOR EVOGUARD
Source text for Eikon: ID:nPnc08kqVa
Further company coverage: EVFM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Evofem Biosciences
See all newsBrief: Evofem Biosciences Adds Additional Manufacturing Capacity For Phexx To Support Global Growth Strategy
Brief: HUB Cyber Security Expands Into Women's Health With Zero-Cash Acquisition Of Evofem Notes
Evofem Biosciences Q1 sales edge up on higher pricing
Evofem Biosciences Q3 net sales rise
Brief: Evofem Anticipates Approval Of Merger With Aditxt At Upcoming Stockholder Meeting